Additionally, our previous research showed that XYS may have therapeutic effects on depression-like behaviors induced by CUMS in mice, possibly mediated by modulation of the glutamate/glutamine cycle and the glutamate transporter GLT-1 in the hippocampus [9]. The gene discussed is SLC1A2; the disease is major depressive disorder.